title: [Relations of tumor-specific cytotoxicity to nonspecific immunological parameters and to clinical course in various surgical cancer patients].
abstract: Human malignant cells, obtained from surgical specimens or pleuro-peritoneal exudate in 105 cases, were cultivated. Tumor-specific immunity was estimated by cytotoxicity assay using mixed autologous lymphocyte-tumor cell culture in 27 cases (40 times in all). Relations of the observed specific immunity to various nonspecific immunological parameters and to clinical responses to immunotherapy were examined. Positive reaction was observed in 14 examinations. Eight of 25 digestive tract cancers and 6 of 15 other cancers were positive. Cytotoxic activity was significantly higher in the group of favorable clinical response than in the group of progressive disease. In the group of positive cytotoxicity, incidence of clinical response was significantly higher than in the group of negative cytotoxicity. A significant positive correlation was found between cytotoxicity and T cell ratio. Incidence of positive cytotoxicity tended to be higher in the cases of single OK-432 administration (6/11). Incidence of clinical response was higher in the cases of combined OK-432 and PSK administration group (4/14). In the positive cytotoxicity group, 3 examinations showed progressive disease and 5 showed no change. It has been suggested that a higher incidence of favorable clinical response is to be expected in case of positive cytotoxicity, if some therapy will be combined with the conventional immunotherapy.
authors.forename: S
authors.initials: S
authors.lastname: Yamamoto
authors.forename: S
authors.initials: S
authors.lastname: Saji
authors.forename: Y
authors.initials: Y
authors.lastname: Sugiyama
authors.forename: H
authors.initials: H
authors.lastname: Kida
authors.forename: T
authors.initials: T
authors.lastname: Umemoto
authors.forename: K
authors.initials: K
authors.lastname: Miya
authors.forename: H
authors.initials: H
authors.lastname: Oshita
authors.forename: Y
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: T
authors.initials: T
authors.lastname: Takekoshi
authors.forename: K
authors.initials: K
authors.lastname: Sakata
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D006801:Humans; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D010844:Picibanil / Q000627:therapeutic use; D011509:Proteoglycans / Q000627:therapeutic use; D011961:Receptors, Fc / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D011509:Proteoglycans; D011961:Receptors, Fc; D010844:Picibanil; C010770:polysaccharide-K